Valneva SE (EPA:VLA)

Market Cap	532.01M
Revenue (ttm)	169.58M
Net Income (ttm)	-12.25M
Shares Out	162.40M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	714,039
Average Volume	1,448,858
Open	3.340
Previous Close	3.354
Day's Range	3.270 - 3.370
52-Week Range	1.726 - 4.298
Beta	1.11
RSI	49.40
Earnings Date	Mar 20, 2025

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 676
• Stock Exchange: Euronext Paris
• Ticker Symbol: VLA

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.